Pfizer’s fourth-quarter profit soared to .27 billion thanks to a huge tax benefit related to the U.S. tax system overhaul.
The biggest U.S. drugmaker on Tuesday reported an .34 billion benefit, mainly from recalculating deferred tax liabilities. Pfizer also said it will take a charge of approximately billion, payable to the Treasury over eight years, to cover taxes on profits held overseas that it plans to bring back to the U.S.
The New York company said those figures may need to be adjusted and did not disclose how much money it will “repatriate.”
Pfizer said it plans over the next five years to invest roughly billion in capital projects in the U.S., including strengthening its U.S. manufacturing “presence.” It plans to spend about million as a one-time bonus for non-executive employees.
The company issued a forecast for adjusted 2018 earnings of .90 to per share, higher than in the past couple of years, with revenue in the range of .5 billion to .5 billion. Due to the tax overhaul, the company said it expects a tax rate of about 17 percent in 2018, well below the 23 percent expected by Credit Suisse analyst Dr. Vamil Divan, he noted in a report.
In early trading Tuesday, shares of Pfizer Inc. fell 94 cents, or 2.4 percent to .08. Numerous other health care stocks also fell on news that Amazon, Warren Buffett’s Berkshire Hathaway and JPMorgan Chase together plan to create a company that would help their U.S. employees find less-expensive quality care.
Pfizer said it’s on track to decide this year whether to keep its consumer health business or sell off all or part of it. It makes household staples including Advil pain reliever, ChapStick and Centrum vitamins.
The maker of Viagra and pain medicine Lyrica said its net income for the fourth quarter amounted to .02. A year earlier, Pfizer posted net income of million, or 13 cents per share.
Adjusted for one-time items, fourth-quarter earnings amounted to .77 billion, or 62 cents per share, 6 cents better than analysts had projected. The per-share earnings were boosted by a low 8.6 percent effective tax rate on fourth-quarter adjusted earnings.
“Pfizer had a strong year in 21017, delivering solid financial results, advancing several significant pipeline programs and enhancing shareholder value,” Chief Executive Ian Read said in a statement. He noted the company won 10 approvals from U.S. regulators last year for new medicines, including new diabetes drug Steglatro and two combo drugs including Steglatro, or for additional uses for existing drugs.
Pfizer posted revenue of .7 billion in the period, up 1 percent and above Street expectations of .61 billion.
Sales growth was led by Lyrica, the Prevnar 13 pneumococcal vaccine and several newer medicines, including clot-preventer Eliquis and rheumatoid arthritis pill Xeljanz.
“This was a strong quarter for Pfizer,” Edward Jones analyst Ashtyn Evans wrote to investors, adding, “We expect sales growth to be minimal in the near term as Pfizer faces the patent expirations of top drugs Viagra and Lyrica. However, we believe that Pfizer has the financial flexibility to add to its product portfolio through potentially sizable acquisitions.”
For all of 2017, Pfizer reported revenue of .55 billion and net income of .31 billion, or .52 per share.
Follow Linda A. Johnson at https://twitter.com/LindaJ_onPharma